Inactive Instrument

Nektar Therapeutics Stock price Nasdaq

Equities

Pharmaceuticals

Sales 2024 * 67.51M Sales 2025 * 68.35M Capitalization 156M
Net income 2024 * -168M Net income 2025 * -167M EV / Sales 2024 * 0.61 x
Net cash position 2024 * 115M Net cash position 2025 * 281M EV / Sales 2025 * -1.83 x
P/E ratio 2024 *
-1 x
P/E ratio 2025 *
-1.27 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.18%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 71 06-12-31
Chairman 66 91-11-30
Director of Finance/CFO 58 23-04-16
Members of the board TitleAgeSince
Director/Board Member 65 09-12-31
Director/Board Member 70 00-07-31
Chairman 66 91-11-30
More insiders
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.
More about the company
  1. Stock
  2. Equities
  3. Stock Nektar Therapeutics
  4. Stock Nektar Therapeutics - Nasdaq